🧠 Food for thought

Implications, context, and why it matters.

Hong Kong’s IPO boom follows a new rulebook

• New listing rules now cover innovative firms that still lose money.
• Chapter 18C, launched in March 2023, sets a path for “Specialist Technology Companies,” including AI and advanced materials 1.
• “Pre-Commercial” companies can list if they meet strict thresholds. These include minimum R&D spending ratios, up to 50% of total operating expenditure for companies with less than HK$150 million revenue in the most recent fiscal year, plus support from two to five Pathfinder Sophisticated Independent Investors (experienced, third-party investors who are independent of the company) at least 12 months before the listing application 1.
• The Greater Bay Area initiative (a Chinese government plan to integrate Hong Kong, Macau, and nearby Guangdong cities into a single economic region) helps Hong Kong-approved drugs and devices reach a market of 86 million people with fewer hurdles 2.

Geopolitics is shifting capital flows toward Hong Kong

• More Chinese companies are steering listings away from Western markets.
• U.S. delisting threats and technology transfer restrictions are pushing Chinese technology, biotechnology, and pharmaceutical firms to focus on Asia. HKEX (Hong Kong Exchanges and Clearing, the city’s stock exchange operator) has become a common landing spot 3.
• Mainland Chinese institutional investors are taking a larger role. Their share of the combined market capitalisation (the total market value of listed shares) of the 30 largest Hong Kong-listed healthcare companies climbed to 44% by June 2025, from 6% in 2017 4.
• Hong Kong led global IPO fundraising in H1 2025 (the first half of 2025), driven largely by dual-listed Mainland firms. That period included clean energy, semiconductors, healthcare, and advanced manufacturing 5.